Table 2.
Author | Trials Design and Conditions Included | No. of Trials (No. of Patients) | Median F/U, mo | Results |
---|---|---|---|---|
Abdel‐Latif46 (2007) | RCT/Co; IHD | 18 (999) | 3–18 | ↑LVEF (3.7%), ↓scar size (−5.5%), ↓LVESV (−4.8 mL) |
Zhao47 (2007) | RCT; IHD, IM/IC | 10 (422) | 3–6 | ↑LVEF (4.6%), ↓LVESVa (−0.4), ↓LVEDVa (−0.4) 6 mo |
Lipinski48 (2008) | RCTs; AMI (<14 d) | 10 (698) | 6 | ↑LVEF (3.0%), ↓scar size (−5.6%), ↓ LVESV (−7.4 mL), ↓recur MI |
Martin‐Rendon49 (2008) | RCTs; AMI (≤7 d) | 13 (811) | 4–6 | ↑LVEF (3.0%), ↓scar size (−3.5%), ↓ LVESV (−4.7 mL) |
Zhang50 (2008) | RCTs; AMI (4–7 d) | 7 (660) | 3–18 | ↑LVEF (4.6%), ↓LVESV (−0.28), ↓CE (OR: 0.32), ↓rest/UA (OR: 0.59) |
Brunskill51 (2009) | RCTs; AMI/IHD, IM/IC | 21 (1091) | 3–6 | IM > IC ↑LVEF (5.9%)b; increase sig. only with lower baseline LVEF in chronic ischemia |
Jeevanantham52 (2012) | RCTs; AMI/IHD, IM/IC | 50 (2625) | ↑LVEF (4.0%), ↓scar size (−4.0%), ↓LVESV (−8.9 mL), ↓LVEDV (−5.2 mL) | |
Delewi53 (2013) | RCT; AMI | 26c (1710) | 6–12 | ↑LVEF (3.9%), ↓scar size NS, ↓LVESV (−9.4 mL), ↓recur AMI (RR: 0.44), ↓read HF, UA (RR: 0.59) |
Fisher54 (2014) | RCT; IHD/HF | 23 (1255) | Variable | ↓Mortality (RR: 0.28), 8 studies; ↑LVEF (−2.6%), 6 studies |
Tian55 | RCT; IM | 11 (492) | 3–12 | ↑LVEF (4.9%), ↓LVESV (−10.7 mL) |
Abbreviations: AMI, acute myocardial infarction; CE, cardiac events; Co, nonrandomized cohort controlled studies; F/U, follow‐up; HF, heart failure; IC, intracoronary injection; IHD, chronic ischemic heart disease; IM, intramyocardial injection; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end‐systolic volume; MI, myocardial infarction; NS, not significant; OR, odds ratio; RCT, randomized controlled trial; read, readmission; recur, recurrent; rest, restenosis; RR, risk ratio; scar size, infarction or scar volume; UA, unstable angina.
IC injections unless otherwise noted.
Weighted mean differences.
IM delivery > IC delivery.
Analysis of 23 studies.